Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

sanofi-aventis
1 Onslow Street, Guildford, Surrey, GU1 4YS, UK
Telephone: +44 (0)1483 505 515
Fax: +44 (0)1483 535 432
Medical Information e-mail: uk-medicalinformation@sanofi-aventis.com

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Summary of Product Characteristics last updated on the eMC: 29/11/2010
SPC Suprax Tablets 200 mg

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 29/11/2010 and displayed until Current
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 8 - MARKETING AUTHORISATION NUMBER(S)
  • Change to section 9 - Date of first Authorisation/renewal of the Authorisation
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   26-Nov-2009
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
Changes made to sections 7, 8, 9 and 10 due to change of ownership from May& baker ltd PL 00012/0316 to Aventis Pharma Limited PL 04425/0623.

7: Contact details for sanofi-aventis remain the same.

8: Changed to PL 04425/0623

9: Date of first authourisation changed to: 26 November 2009

10: Date of revision of the text: 26 November 2009
Updated on 31/07/2008 and displayed until 29/11/2010
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable Effects
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   04-Jul-2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
Addition of the following side effects to section 4.8;

angioedema
Thrombocytosis,
hypereosinophilia,
neutropenia
agranulocytosis
Updated on 18/09/2007 and displayed until 31/07/2008
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
Date of revision of text on the SPC:   11/2006
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
Section 7 (Marketing Authorisation Holder): Change in MA Holder's details

                                                                                               
Updated on 07/06/2006 and displayed until 18/09/2007
Reasons for adding or updating:
  • Change from BAN to rINN
Date of revision of text on the SPC:   7/5/06
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
Section 4.1 and 5.1 change of BAN to INN: Methicillin to meticillin
Updated on 14/06/2004 and displayed until 07/06/2006
Reasons for adding or updating:
  • Addition of separate SPCs covering individual presentations

Active Ingredients/Generics

 
  cefixime